Drawing inferences on Tarceva

Drawing inferences on Tarceva

OSI Pharmaceuticals Inc. expects that last week's protocol amendment to its Phase III TRIBUTE trial of Tarceva to treat non-small cell lung cancer will not affect the primary endpoint of survival. Instead, OSIP maintains that the lesson learned from the amendment is not to cram too much into a given study. ...